Tissue | Expression Dynamics | Abbreviation |
Breast | | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Lung | | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00971939 | Breast | Precancer | intrinsic apoptotic signaling pathway | 59/1080 | 288/18723 | 8.07e-18 | 3.60e-15 | 59 |
GO:20012339 | Breast | Precancer | regulation of apoptotic signaling pathway | 65/1080 | 356/18723 | 7.70e-17 | 3.17e-14 | 65 |
GO:20012429 | Breast | Precancer | regulation of intrinsic apoptotic signaling pathway | 41/1080 | 164/18723 | 6.48e-16 | 2.31e-13 | 41 |
GO:00525479 | Breast | Precancer | regulation of peptidase activity | 71/1080 | 461/18723 | 2.72e-14 | 6.94e-12 | 71 |
GO:00525489 | Breast | Precancer | regulation of endopeptidase activity | 67/1080 | 432/18723 | 1.06e-13 | 2.36e-11 | 67 |
GO:20001169 | Breast | Precancer | regulation of cysteine-type endopeptidase activity | 43/1080 | 235/18723 | 1.30e-11 | 1.83e-09 | 43 |
GO:00432819 | Breast | Precancer | regulation of cysteine-type endopeptidase activity involved in apoptotic process | 40/1080 | 209/18723 | 1.59e-11 | 2.07e-09 | 40 |
GO:20012349 | Breast | Precancer | negative regulation of apoptotic signaling pathway | 39/1080 | 224/18723 | 5.35e-10 | 4.77e-08 | 39 |
GO:00458619 | Breast | Precancer | negative regulation of proteolysis | 50/1080 | 351/18723 | 2.99e-09 | 2.39e-07 | 50 |
GO:20012439 | Breast | Precancer | negative regulation of intrinsic apoptotic signaling pathway | 23/1080 | 98/18723 | 5.82e-09 | 4.45e-07 | 23 |
GO:00086378 | Breast | Precancer | apoptotic mitochondrial changes | 23/1080 | 107/18723 | 3.44e-08 | 2.12e-06 | 23 |
GO:00513468 | Breast | Precancer | negative regulation of hydrolase activity | 50/1080 | 379/18723 | 3.85e-08 | 2.34e-06 | 50 |
GO:00104668 | Breast | Precancer | negative regulation of peptidase activity | 38/1080 | 262/18723 | 1.46e-07 | 7.82e-06 | 38 |
GO:00109519 | Breast | Precancer | negative regulation of endopeptidase activity | 37/1080 | 252/18723 | 1.55e-07 | 8.05e-06 | 37 |
GO:20001179 | Breast | Precancer | negative regulation of cysteine-type endopeptidase activity | 19/1080 | 86/18723 | 3.36e-07 | 1.58e-05 | 19 |
GO:00457859 | Breast | Precancer | positive regulation of cell adhesion | 52/1080 | 437/18723 | 5.74e-07 | 2.49e-05 | 52 |
GO:00511019 | Breast | Precancer | regulation of DNA binding | 22/1080 | 118/18723 | 9.28e-07 | 3.71e-05 | 22 |
GO:00431548 | Breast | Precancer | negative regulation of cysteine-type endopeptidase activity involved in apoptotic process | 17/1080 | 78/18723 | 1.69e-06 | 6.08e-05 | 17 |
GO:00433887 | Breast | Precancer | positive regulation of DNA binding | 14/1080 | 56/18723 | 2.46e-06 | 8.35e-05 | 14 |
GO:00510989 | Breast | Precancer | regulation of binding | 44/1080 | 363/18723 | 2.59e-06 | 8.65e-05 | 44 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PLAUR | SNV | Missense_Mutation | rs750492027 | c.829N>A | p.Ala277Thr | p.A277T | Q03405 | protein_coding | tolerated(0.19) | benign(0.018) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PLAUR | SNV | Missense_Mutation | | c.198N>G | p.Ser66Arg | p.S66R | Q03405 | protein_coding | deleterious(0) | benign(0.284) | TCGA-AR-A24Q-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
PLAUR | insertion | In_Frame_Ins | novel | c.389_390insTCCCCTGGCCCCCATAGGGCGTCCAAAGGATGA | p.Gly130_Arg131insProLeuAlaProIleGlyArgProLysAspAsp | p.G130_R131insPLAPIGRPKDD | Q03405 | protein_coding | | | TCGA-A8-A09A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
PLAUR | SNV | Missense_Mutation | | c.346G>A | p.Glu116Lys | p.E116K | Q03405 | protein_coding | deleterious(0.01) | probably_damaging(0.987) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
PLAUR | SNV | Missense_Mutation | rs756038834 | c.814N>A | p.Ala272Thr | p.A272T | Q03405 | protein_coding | tolerated(0.3) | benign(0.042) | TCGA-NH-A5IV-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PLAUR | SNV | Missense_Mutation | | c.118G>T | p.Ala40Ser | p.A40S | Q03405 | protein_coding | tolerated(0.21) | benign(0.028) | TCGA-AF-4110-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | I/II | Chemotherapy | oxaliplatin | SD |
PLAUR | SNV | Missense_Mutation | novel | c.979N>A | p.Leu327Met | p.L327M | Q03405 | protein_coding | deleterious_low_confidence(0.02) | possibly_damaging(0.533) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PLAUR | SNV | Missense_Mutation | novel | c.389N>A | p.Gly130Asp | p.G130D | Q03405 | protein_coding | deleterious(0.01) | benign(0.264) | TCGA-AJ-A23O-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PLAUR | SNV | Missense_Mutation | novel | c.668N>T | p.Ser223Ile | p.S223I | Q03405 | protein_coding | deleterious(0) | probably_damaging(0.959) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PLAUR | SNV | Missense_Mutation | | c.252N>T | p.Lys84Asn | p.K84N | Q03405 | protein_coding | deleterious(0.03) | benign(0.213) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5329 | PLAUR | DRUGGABLE GENOME, ENZYME, CELL SURFACE | | ADENOVIRAL VECTOR | | 12955075 |
5329 | PLAUR | DRUGGABLE GENOME, ENZYME, CELL SURFACE | | UROKINASE | UROKINASE | |
5329 | PLAUR | DRUGGABLE GENOME, ENZYME, CELL SURFACE | | RECOMBINANT INTERFERON GAMMA | | 8049441 |
5329 | PLAUR | DRUGGABLE GENOME, ENZYME, CELL SURFACE | | G-CSF | FILGRASTIM | 15747404 |
5329 | PLAUR | DRUGGABLE GENOME, ENZYME, CELL SURFACE | | MCP-2 | | 12138365 |
5329 | PLAUR | DRUGGABLE GENOME, ENZYME, CELL SURFACE | | DIPHTHERIA TOXIN | | 11959893 |
5329 | PLAUR | DRUGGABLE GENOME, ENZYME, CELL SURFACE | | Ruxolitinib | RUXOLITINIB | |
5329 | PLAUR | DRUGGABLE GENOME, ENZYME, CELL SURFACE | | PHORBOL MYRISTATE ACETATE | | 9531044 |